KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-cash Items (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Non-cash Items data on record, last reported at $326.1 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 5.51% year-over-year to $326.1 million; the TTM value through Dec 2025 reached $474.0 million, up 5900.0%, while the annual FY2025 figure was $474.0 million, 5900.0% up from the prior year.
  • Non-cash Items reached $326.1 million in Q4 2025 per REGN's latest filing, up from $158.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $1.1 billion in Q1 2022 and bottomed at -$1.1 billion in Q2 2024.
  • Average Non-cash Items over 5 years is $79.5 million, with a median of $106.5 million recorded in 2023.
  • The widest YoY moves for Non-cash Items: up 593.71% in 2024, down 2096.85% in 2024.
  • A 5-year view of Non-cash Items shows it stood at -$446.7 million in 2021, then skyrocketed by 217.04% to $522.8 million in 2022, then crashed by 113.37% to -$69.9 million in 2023, then surged by 593.71% to $345.1 million in 2024, then decreased by 5.51% to $326.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $326.1 million in Q4 2025, $158.7 million in Q3 2025, and -$247.2 million in Q2 2025.